MDX-2001, a potent tetraspecific T-cell engager with minimal T-cell activation in the absence of tumor cells
Nov. 15, 2024
MDX-2001 (Modex Therapeutics Inc.) was engineered as a potentially first-in-class tetraspecific lymphocyte activator and survival enhancement receptor (LASER) recognizing CD3 and CD28 on human T cells and c-MET and TROP2 on tumor cells.
